Spyre Therapeutics
SYRE
SYRE
66 hedge funds and large institutions have $25.4M invested in Spyre Therapeutics in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 21 increasing their positions, 17 reducing their positions, and 28 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less funds holding in top 10
Funds holding in top 10: →
54% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 28
73% less capital invested
Capital invested by funds: $95.4M → $25.4M (-$70M)
Holders
66
Holding in Top 10
1
Calls
$23K
Puts
–
Top Buyers
| 1 | +$1.92M | |
| 2 | +$1.26M | |
| 3 | +$1.26M | |
| 4 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$1.18M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$758K |
Top Sellers
| 1 | -$3.62M | |
| 2 | -$1.19M | |
| 3 | -$1M | |
| 4 |
BlackRock
New York
|
-$935K |
| 5 |
Nuveen Asset Management
Chicago,
Illinois
|
-$425K |